Vensana Capital is a venture capital and growth equity firm that invests in development- and commercial-stage companies across the medtech sector. Their strategy involves providing capital and partnership to entrepreneurs innovating in areas such as medical devices, diagnostics and data science, drug delivery, digital health, life-science tools, and tech-enabled services.
89% of their portfolio is in Healthcare. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (44% of deals). Average disclosed round size is $40.3M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
$1B
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ventaris Surgical, Inc. | Series A | $30M | Jan 2026 |
 SpyGlass Pharma | Series D | $75M | Jun 2025 |
 Okami Medical | Unknown | $32.5M | Oct 2024 |
 Relievant Medsystems | Series G | $50M | Apr 2023 |
 Nyra Medical, Inc. | Series A | $20M | Nov 2022 |
 Apella | Series A | $21M | Dec 2021 |
| CCleerly Coronary | Series B | $43M | Jun 2021 |
| Relievant Medsystems | Unknown | $70M | Oct 2020 |
| AApella Technology | Series A | $21M | — |
Top Co-Investors
Canaan Partners2 shared
Endeavour Vision2 shared
Lightstone Ventures2 shared
Morgenthaler Ventures2 shared
Broadview Ventures1 shared
U.S. Venture Partners1 shared
New Leaf Venture Partners1 shared
DigiTx Partners1 shared
Cigna Ventures1 shared
Ally Bridge Group1 shared
Sands Capital1 shared
Gilde Healthcare1 shared
RA Capital Management1 shared
Samsara BioCapital1 shared
Vertex Ventures HC1 shared
Longitude Capital1 shared
Atypical1 shared
Neotribe1 shared
Boutique Venture Partners1 shared
Last updated: 16 April 2026